stockrow
Monday 9 November 2026
Export MENS’s income statement to Excel — free account
Jyong Biotech Ltd.
MENS
1.80
0.15
+9.09%
Follow MENS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | (4) | (3) | (5) | +3.0% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | (4) | (3) | (5) | +3.0% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (0.06) | (0.04) | (0.06) | (1.2%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (0.04) | (0.05) | (0.04) | +7.2% | ||||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | (0.04) | (0.05) | (0.04) | +7.2% | ||||||
| Book value | — | — | — | — | — | — | — | (0.48) | (0.51) | (0.34) | (15.4%) | ||||||
| Shares, m | — | — | — | — | — | — | — | 72 | 72 | 73 | +1.0% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (3) | (4) | (3) | +8.1% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | (3) | (4) | (3) | +8.1% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (12) | (12) | (19) | +24.6% | |||||
| Net debt | — | — | — | — | — | — | — | 15 | 18 | 17 | +8.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (34) | (37) | (25) | (14.5%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (41.32) | (34.42) | (34.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 8.55 | 15.21 | +15.2 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 29 | 27 | (6.9%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Jyong Biotech Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| CMPX Compass Therapeutics, Inc. | $136.7M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $133.8M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MENS Jyong Biotech Ltd. | $133.6M | — | — | — | — | — | — | — | |
| PDSB PDS Biotechnology Corporation | $129.2M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PYPD PolyPid Ltd. | $124.7M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $119.2M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +11.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CHRS Coherus Oncology, Inc. | $119.0M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| Median of peers | $131.5M | — | — | −18.17% | — | −27.08% | 35.18% | 0.00% |